Linagliptin KRIJENTA 5mg Tablet – Trusted DPP-4 Inhibitor for Type 2 Diabetes Management
Linagliptin (KRIJENTA) 5mg Tablet
Linagliptin (KRIJENTA) 5mg Tablet is an oral medication used for the management of Type 2 Diabetes Mellitus (T2DM). It belongs to a class of medications known as Dipeptidyl Peptidase-4 (DPP-4) inhibitors. Linagliptin helps control blood sugar levels by increasing the levels of incretin hormones in the body, which in turn stimulate insulin release and decrease glucagon secretion in a glucose-dependent manner. Unlike many traditional diabetes treatments, Linagliptin works with the body’s natural mechanisms and is associated with a lower risk of hypoglycemia and weight gain.
What sets Linagliptin apart is that it does not require dosage adjustment in patients with kidney disease, making it a preferred option among people with varying degrees of renal impairment. This once-daily tablet offers convenience, safety, and efficacy for long-term glycemic control.
Indications
Linagliptin KRIJENTA 5mg Tablet is indicated for:
-
As monotherapy for adults with Type 2 Diabetes Mellitus who are unable to achieve adequate glycemic control with diet and exercise alone.
-
As combination therapy with:
-
Metformin
-
Sulfonylureas
-
Thiazolidinediones
-
Insulin
-
Note: Linagliptin is not indicated for the treatment of Type 1 Diabetes Mellitus or diabetic ketoacidosis.
Mechanism of Action
Linagliptin KRIJENTA 5mg Tablet functions by selectively inhibiting the DPP-4 enzyme. DPP-4 breaks down incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These incretin hormones play a crucial role in regulating glucose homeostasis by enhancing insulin secretion and suppressing glucagon production when glucose levels are elevated.
As a result, Linagliptin:
-
Increases insulin production in a glucose-dependent manner
-
Reduces hepatic glucose output
-
Minimizes the risk of hypoglycemia
-
Offers sustained glycemic control
Uses and Benefits Linagliptin (KRIJENTA) 5mg Tablet
1. Effective Glycemic Control
Linagliptin lowers fasting and postprandial blood glucose levels. It also helps reduce HbA1c levels, a marker for long-term glucose control.
2. Kidney-Friendly Option
One of the most significant advantages of Linagliptin is that it does not require dose adjustment in patients with kidney impairment, unlike other DPP-4 inhibitors.
3. Minimal Risk of Hypoglycemia
When used as monotherapy or with non-hypoglycemic drugs like metformin, Linagliptin carries a low risk of causing low blood sugar levels.
4. Weight Neutral
Unlike sulfonylureas or insulin, Linagliptin is weight neutral, which is important for overweight or obese patients managing Type 2 Diabetes.
5. Convenient Dosing
Linagliptin is typically administered as a once-daily 5 mg tablet, simplifying adherence for patients.
Dosage and Administration for Linagliptin (KRIJENTA) 5mg Tablet
The recommended dose of Linagliptin is 5 mg once daily, with or without food. The tablet should be taken at the same time each day for optimal results.
No dosage adjustments are necessary for patients with:
-
Mild, moderate, or severe renal impairment
-
Hepatic impairment
However, dose modifications may be necessary when Linagliptin is combined with other antidiabetic medications, particularly those that may increase the risk of hypoglycemia, like sulfonylureas or insulin.
Precautions and Warnings for Linagliptin (KRIJENTA) 5mg Tablet
Before initiating Linagliptin, consult your physician and consider the following precautions:
-
Pancreatitis: Cases of acute pancreatitis have been reported. Discontinue Linagliptin if symptoms such as persistent abdominal pain occur.
-
Hypersensitivity Reactions: Though rare, serious allergic reactions like angioedema and urticaria can occur.
-
Arthralgia: Joint pain has been observed with DPP-4 inhibitors, including Linagliptin.
-
Heart Failure Risk: Use caution in patients with a history of heart failure, particularly when combined with other medications like pioglitazone.
Side Effects
Linagliptin (KRIJENTA) 5mg Tablet is generally well-tolerated, but some patients may experience side effects, which can include:
Common Side Effects:
-
Nasopharyngitis
-
Cough
-
Headache
-
Back pain
Less Common but Serious Side Effects:
-
Pancreatitis
-
Hypoglycemia (especially when used with insulin or sulfonylureas)
-
Skin reactions (rash, itching)
-
Hypersensitivity reactions
If any severe reactions or symptoms persist, seek immediate medical attention.
Drug Interactions
Linagliptin (KRIJENTA) 5mg Tablet has a low potential for drug interactions but may interact with:
-
Rifampin (may reduce the effectiveness of Linagliptin)
-
Sulfonylureas or insulin (increased risk of hypoglycemia)
-
ACE inhibitors or diuretics (risk of hypotension or renal effects in susceptible patients)
Always inform your healthcare provider of all medications and supplements you are taking before starting Linagliptin.
Storage Information
To maintain potency and safety, store Linagliptin (KRIJENTA) 5mg Tablet under the following conditions:
-
Keep in original packaging
-
Store at 20°C to 25°C (68°F to 77°F)
-
Protect from excessive heat, moisture, and light
-
Keep out of reach of children
Do not use Linagliptin past its expiration date, and dispose of expired tablets properly according to local regulations.
FAQs
Q: Can Linagliptin be used with insulin?
Yes, Linagliptin can be safely used with insulin, but caution is advised to avoid hypoglycemia.
Q: Is Linagliptin safe during pregnancy or breastfeeding?
There is limited data on Linagliptin use during pregnancy and lactation. Consult your healthcare provider before use.
Q: How long does it take for Linagliptin to work?
Improvements in blood sugar control can be seen within a few weeks, with full HbA1c reductions typically visible in 2–3 months.
Further Reading and References
To know more about this product, please contact us.
Reviews
There are no reviews yet.